Navigation Links
Reportlinker Adds Pharmaceutical Key Trends 2011 - Pharmaceutical Industry Infrastructure Overview: Pharma innovates, diversifies and contains cost in order to grow profits
Date:4/26/2011

NEW YORK, April 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceutical Key Trends 2011 - Pharmaceutical Industry Infrastructure Overview: Pharma innovates, diversifies and contains cost in order to grow profits

http://www.reportlinker.com/p0484917/Pharmaceutical-Key-Trends-2011----Pharmaceutical-Industry-Infrastructure-Overview-Pharma-innovates-diversifies-and-contains-cost-in-order-to-grow-profits.html

Pharma companies face a number of resistors to profit growth including the looming patent cliff causing a significant slowing in branded sales, coupled with ongoing R&D challenges. Pharma companies are therefore taking by boosting performance through enhancing operating profit through a combination of operating margin and sales growth.Examines the drivers and resistors facing branded pharmaceutical companiesAnalyzes M&A deals by the leading pharmaceutical companies between 2008 and 2010Examines the ongoing challenges in R&D and different strategies to overcome these hurdlesProvides an overview of various cost cutting strategies and how these are being implemented by Big PharmaWith the era of the traditional blockbuster growth model coming to an end, pharma companies are moving towards innovative, often biologic therapies for niche indications with a high unmet need, in order to gain market superiority and drive future sales growth. However, such strategies are often long-term and carry significant risk.Pharma companies are increasingly looking to expand beyond branded pharmaceuticals in the developed markets, towards generics and biosimilars, entry into the emerging markets, as well as looking outside pharmaceuticals altogether. While this can mitigate a company's risk, margins can be diluted.M&A offer the opportunity to grow scale and cut costs through elimination of duplicate operations, while externalization of R&D enables low-risk access to innovative pipeline products. Ultimately, such strategies can be used to increase profitability, although M&A at least in the long term is not a sustainable strategy.Assess the evolving R&D sector and how this is being impacted by on-going cost cutting strategies.Case study analysis of various restructuring and cost saving measures.Evaluate how M&A deals are being utilized to cut costs, drive innovation and diversify.

Executive Summary

Introduction

Strategic scoping and focus

Key findings

Key growth drivers and resistors facing healthcare payers and pharma

Pharma's strategic responses to drive sales and profitability

Cost-cutting strategies

M&A utilized to cut costs, drive innovation, and diversification

Pharma continues to battle with R&D issues

Related reports

Upcoming related reports

COST CUTTING

Pharma cuts costs to improve profitability

Cost-cutting has ultimately led to site closures and job cuts

Restructuring and greater externalization continues to impact employment levels in pharma

Pharma continues to cut R&D and manufacturing sites

Mega-M&A used to grow scale and cut costs

CMOs and CROs set to capitalize on the growing need to reduce in-house R&D and manufacturing

CMO market set to boom but inspections must increase

Fragmented CRO market set to become more competitive

Restructuring as part of a shift in R&D focus led to site closures

Bristol-Myers Squibb is divesting its ex-pharma units to increase operating margins and generate cash for a small acquisition

Pharma cuts promotional budgets for expiring blockbusters

Reducing bonuses is an alternative option to cost cutting

MERGERS AND ACQUISITIONS

M&A activity has bounced back

M&A utilized to cut costs, drive innovation, and diversification

Big Pharma M&A to enhance focus on specialty pharmaceuticals

M&A driven by diversification/specialization

Mega-M&A deals to cut costs and increase scale

RESEARCH AND DEVELOPMENT

Pharma continues to battle with R&D issues

Falling productivity and growing costs hamper pharma's R&D

The Obama administration aims to accelerate early-stage research

R&D spend continues to grow in a desperate effort to replenish pipelines

Pharma is increasingly externalizing R&D to cut costs and mitigate risks

Pharma's level of early-stage R&D collaboration intensifies

R&D outsourcing and offshoring to grow further as pharma's focus on cost-containment heightens

Pharma sharpens its focus on secondary care indications through high value biologic therapies

Restructuring driven by thinning pipelines

Drug approvals dipped in 2010

Orphan drug designations reached a record high in 2010

Key Big Pharma players targeting niche pharma markets

Key technologies utilized by pharma when targeting rare diseases

Development of RNAi therapies among major industry players has stalled

Companion diagnostics can optimize the commercial potential of novel drugs

2010 marked the beginning of a new era for stem cell research, with 2011 looking to be even more promising

Biotech show signs of recovery

Biotech financing shows steady growth driven by greater levels of debt financing

Biotech IPOs point to a gradual recovery in investor confidence

However, IPOs were less lucrative than anticipated

Fewer bankruptcies in 2010 reflect an improving funding environment for biotechs

BIBLIOGRAPHY

Publications and online articles

Datamonitor reports and products

APPENDIX

Exchange rates used in this report

To order this report:

: Pharmaceutical Key Trends 2011 - Pharmaceutical Industry Infrastructure Overview: Pharma innovates, diversifies and contains cost in order to grow profits

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Epidemiology: Rheumatoid Arthritis
2. Reportlinker Adds Epidemiology: Multiple Sclerosis
3. Reportlinker Adds Epidemiology: Lupus
4. Reportlinker Adds Epidemiology: Prostate Cancer
5. Reportlinker Adds Medical Equipment Monthly Deals Analysis - M&A and Investment Trends, April 2011
6. Reportlinker Adds Body Contouring Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
7. Reportlinker Adds Ophthalmology DrugFutures
8. Reportlinker Adds Europe ENT Devices Market Outlook to 2017
9. Reportlinker Adds Medical Equipment Annual Deals Analysis 2011
10. Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds
11. Reportlinker Adds the Drug-Eluting Stent Market Outlook to 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):